

TITLE:

Rate of Force Development is Related to Maximal Force, Muscle Quality and Physical Function in Patients With Chronic Kidney Disease Predialysis

AUTHORS:

Jared M. Gollie, PhD, CSCS^{1,2,3}, Michael O. Harris-Love, PT, MPT, DSc, FGSA^{4,5}, Samir S. Patel, MD^{6,7}, Marc R. Blackman, MD^{8,9,10}

AFFILIATIONS:

1. Skeletal Muscle Laboratory, Human Performance Research Unit, Clinical Research Center, Veterans Affairs Medical Center, Washington, DC 20422, USA
2. Department of Health, Human Function, and Rehabilitation Sciences, School of Medicine and Health Sciences, The George Washington University, Washington DC 20052, USA
3. Rehabilitation Science Department, College of Health and Human Services, George Mason University, Fairfax, Virginia 22030, USA
4. Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
5. Geriatric Research Education and Clinical Center, VA Eastern Colorado Healthcare System, Aurora, Colorado 80045, USA
6. Renal Service, Veterans Affairs Medical Center, Washington, DC 20422, USA
7. Department of Medicine, School of Medicine and Health Sciences, The George Washington University, Washington DC 20052, USA
8. Laboratory of Geriatric Endocrinology and Metabolism, Veterans Affairs Medical Center, Washington, DC 20422, USA
9. Departments of Medicine and Rehabilitation Medicine, School of Medicine, Georgetown University, Washington, DC 20007, USA
10. Departments of Medicine and Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington DC 20037, USA

CORRESPONDING AUTHOR:

Jared M. Gollie, PhD, CSCS

jared.gollie@gmail.com

202-745-8000 ext: 55851

ORCID: 0000-0003-1066-7389

ClinicalTrials.gov NCT03160326

1 **ABSTRACT**

2 *Background* Physical function is severely compromised in people with chronic kidney disease
3 (CKD) and worsens with continued decreases in kidney function. Neuromuscular force capacity
4 is a key determinant of physical function in healthy older adults, though its importance in
5 persons with CKD is less understood. *Methods* This study aimed to determine the relationships
6 among rate of force development (RFD), muscle quality and physical function in a group of
7 community-dwelling, middle-aged and older men (n=14; age=71.2±6.2 years) with CKD stages
8 3 and 4 (eGFR=37.5±10.4 ml/min per 1.73 m²). Force characteristics were determined from
9 maximal knee extensor isometric contractions and muscle quality was estimated using
10 ultrasound grayscale analysis. Physical function was assessed by the Short Physical
11 Performance Battery (SPPB) and 5-repetition sit-to-stand (STS) test. *Results* eGFR was directly
12 related to SPPB (r=0.54, p=0.044) and inversely related to STS (r=-0.62, p=0.029). RFD was
13 positively related to SPPB at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD₀₋₅₀, r=0.73,
14 p=0.010; RFD₅₀₋₁₀₀, r=0.67, p=0.022 and RFD₀₋₃₀₀ r=0.61, p=0.045); and inversely related to STS
15 at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD₀₋₅₀, r=-0.78, p=0.007; RFD₅₀₋₁₀₀, r=-0.78,
16 p=0.006 and RFD₀₋₃₀₀ r=-0.76, p=0.009), respectively. RFD was positively associated with
17 maximal voluntary force (MVF) at times 50-100 ms, 100-200 ms, and 0-300 ms (RFD₅₀₋₁₀₀,
18 r=0.72, p=0.011; RFD₁₀₀₋₂₀₀, r=0.66, p=0.025; and RFD₀₋₃₀₀ r=0.70, p=0.016), respectively.
19 Neither MVF nor muscle quality was significantly associated with functional measures.
20 *Conclusions* RFD is an important determinant of physical function in middle-aged and older men
21 with CKD stages 3 and 4.

22 **KEYWORDS**

23 Chronic kidney disease; rate of force development; strength; muscle quality; physical function

24 **INTRODUCTION**

25 Physical function is severely compromised in people with chronic kidney disease (CKD) and has
26 been shown to be predictive of risk of hospitalization, disability and mortality (10, 16, 17, 25, 26,
27 28, 30, 33). For example, individuals with low functional status at the time of dialysis initiation
28 experience a higher risk of all-cause mortality irrespective of age and history of cardiovascular
29 disease (10). Similarly, functional measures of gait speed and timed-up-and-go are better
30 predictors of 3-year mortality than are kidney function or commonly measured serum
31 biomarkers in patients with CKD predialysis (29).

32
33 Rate of force development (RFD) describes the rate at which force is expressed during fast and
34 forceful contractions and has become recognized as an underlying factor contributing to
35 physical function in older adults (8, 24). Early time intervals (i.e., <75 ms) of RFD are thought to
36 be primarily influenced by neural factors, whereas muscular factors become increasingly
37 important with greater time from onset of contraction (3, 20, 27). However, Gerstner et al.
38 reported that age-associated declines in rapid torque production during later time intervals (i.e.,
39 ≥ 100 ms) are influenced by alterations in muscle quality, architecture, and muscle activation (4).

40
41 Accelerated skeletal muscle loss is a major concern in patients with CKD and end-stage renal
42 disease (ESRD) (34). Reductions in muscle cross-sectional area have been associated with
43 declines in physical function (13, 21). Neurological complications, including peripheral
44 neuropathy, are also highly prevalent in patients with CKD (1, 15). Accordingly, both neural and
45 muscle morphological alterations are potential factors contributing to muscle weakness. The
46 loss in neuromuscular force is reported to occur more rapidly than changes in muscle cross-
47 sectional area in patients with CKD predialysis and ESRD (14, 18). Moreover, changes in
48 muscle cross-sectional area have been found to be poorly associated with changes in functional
49 outcomes (14). Taken together, these observations further highlight the potential contributions

50 of neural alterations, in addition to muscle morphological properties, on neuromuscular capacity
51 in patients with CKD.

52

53 Currently, there is little information describing neuromuscular contributions to physical function
54 in patients with CKD predialysis. Consequently, the effects of compromised force characteristics
55 and muscle quality, if present, on physical function in those with CKD predialysis are unclear. In
56 this study, we aimed to determine the relationships among RFD, muscle quality and physical
57 function in patients with CKD stages 3 and 4 predialysis. We hypothesized that RFD, maximal
58 voluntary force (MVF), and muscle quality would be significantly associated with physical
59 function in patients with CKD stages 3 and 4.

60

61 **METHODS**

62 *Study Design.* A single cohort, cross-sectional study design was used to examine the
63 relationships among knee extensor RFD, maximum voluntary force (MVF), muscle quality of the
64 rectus femoris (RF), and sit-to-stand (STS) time in a convenience sample of middle-aged and
65 older men with CKD stages 3 and 4 seen at a Veterans Affairs Medical Center. Data were
66 collected by trained staff in the Renal Clinic, and Physical Medicine and Rehabilitation and
67 Research Service groups at the Veterans Affairs Medical Center in Washington, DC (DC
68 VAMC) and the study was registered with ClinicalTrials.gov (NCT03160326).

69

70 *Participants and Ethical Approval.* Community-dwelling male Veterans were screened and
71 referred by the Renal Clinic staff at the DC VAMC for potential enrollment. The study was
72 approved by the DC VAMC Institutional Review Board and Research and Development
73 Committee. Inclusion criteria for study enrollment required participants to be ambulatory, with or
74 without use of an assistive device, aged 18-85 years, and diagnosed with CKD stage 3 or 4,
75 based on eGFR measures obtained within the 3-months prior to study enrollment. Exclusion

76 criteria included a history of acute kidney injury, any uncontrolled cardiovascular or
77 musculoskeletal problems, or having a pacemaker or implantable cardioverter defibrillator. All
78 participants voluntarily provided written informed consent using an IRB approved form prior to
79 study participation.

80

81 *Procedures.* Each participant reported to the Skeletal Muscle Laboratory in the Clinical
82 Research Center at the DC VAMC to complete neuromuscular strength, muscle quality and
83 physical function assessments. Participants were asked to refrain from any vigorous activity for
84 at least 24 hours before testing. Quantitative ultrasound imaging preceded strength and
85 functional testing. At least 30-minutes was allotted between strength and functional
86 assessments to minimize the potential for test contamination due to fatigue.

87

88 *Diagnostic Ultrasound Assessments.* Methods used for diagnostic ultrasound assessments
89 have previously been published (9, 11). Sonographic images were obtained using B-mode
90 diagnostic ultrasound with a 5-18 MHz linear array transducer (Nobulus, Hitachi Aloka Medical,
91 Parsippany, NJ). Manufacturer default settings for time gain compensation and near field/far
92 field gain were applied for all musculoskeletal scans. The field of view was adjusted for each
93 participant to optimally capture the region of interest (ROI) of the RF on the dominant side.
94 Standardized procedures were followed for the identification of the scanning site, as previously
95 described (9, 11). Scanned images were obtained by a single clinical investigator (MHL) with
96 more than 10 years of quantitative ultrasound experience.

97

98 *Quantitative Strength Testing.* Knee extensor strength of the dominant leg was assessed using
99 a portable fixed dynamometer (FGV-200XY, NIDEC instruments, Itasca, IL). The dynamometer
100 was securely mounted and anchored behind the participant. Participants were placed in the
101 seated position on the edge of an adjustable examination table and with their hips and knees at

102 90° of flexion. A strap attached to the dynamometer was secured around the ankle of the
103 dominant leg. Participants were allowed to use their hands for stability but were asked to refrain
104 from grasping onto the table. A familiarization session was provided before data collection to
105 orient each participant to the isometric testing procedures. Participants were instructed to
106 extend or kick their leg as “hard” as possible following the test administrator’s requests, and to
107 contract and sustain the contraction for 5-seconds while being provided strong verbal
108 encouragement. A rest period of approximately 1-minute was provided between repetitions. Pre-
109 contraction tension and countermovement were removed by test administrators and the
110 dynamometer was zeroed just before contraction initiation.

111

112 *Short Physical Performance Battery (SPPB)*. The SPPB is a measure used to assess lower
113 extremity function and is predictive of subsequent disability in persons over 70 years of age (6).
114 The SPPB is composed of tasks assessing balance, walking speed, and the ability to rise from a
115 chair. A composite score is generated with the highest possible score being 12. Those
116 completing the respective tasks were assigned a score of 1 to 4 on each task, with higher
117 scores representative of better performance of the task. Participants unable to complete a task
118 were given a score of zero for that task. Complete details of the SPPB have been described
119 elsewhere (7).

120

121 *Sit-to-Stand (STS)*. For the purposes of this study we also examined the STS task independent
122 of the SPPB as the ability to rise from a chair repeatedly has been used as a measure to assess
123 lower extremity power (32). STS determined as the time taken to complete 5 sit-to-stand
124 repetitions. The test was stopped if the participant became tired or short of breath, used his
125 arms, was unable to complete the five repetitions within one-minute, or if the test administrator
126 became concerned about the participant’s safety.

127

128 **Data analysis.**

129 *Quantitative Ultrasound.* All scanned images were obtained and measured 3 times within the
130 fascial borders of the muscle. The ROI selection and echogenicity measures of the RF via
131 grayscale (GSL) histogram analysis were completed using ImageJ (version 1.48; National
132 Institutes of Health, Bethesda, MD, USA). ROI was defined as the area within the superior and
133 inferior fascial borders and the lateral borders of the RF. In those instances when a portion of a
134 fascial border was poorly visualized, the examiner used the trajectory of the visible fascial
135 border to complete the ROI selection (11). Subcutaneous fat was quantified according to
136 methods described by Stock et al. (31). The mean of the three thickness values from each
137 image was utilized. GSL values were then corrected for subcutaneous fat using the following
138 equation (31): corrected GSL = uncorrected GSL + (subcutaneous fat thickness [cm] x
139 40.5278).

140
141 *Strength Testing.* The real-time force applied to the dynamometer was displayed online on a
142 computer monitor. Force data were sampled at 100Hz and digitally stored to be analyzed offline.
143 No more than six maximal voluntary isometric contractions were completed during strength
144 assessments. Peak isometric knee extensor strength was determined by averaging 3 attempts
145 which fell within 10% of each other or the 3 highest values of the six attempts. Rate of force
146 development (RFD) was calculated as the change in force by change in time following the
147 initiation of isometric knee extension contraction and assessed over consecutive time epochs;
148 0-50 ms, 50-100 ms, 100-200 ms, and 200-300 ms (i.e., RFD_{0-50} , RFD_{50-100} , $RFD_{100-200}$, and
149 $RFD_{200-300}$). RFD was also calculated as the change in force by the change in time over the first
150 300 ms of the contraction (i.e., RFD_{0-300}) (**Figure 1**). The onset of contraction was determined as
151 the first derivative of the filtered force signaling that crossed 2.5% of peak force (20). In addition
152 to absolute RFD, RFD is expressed relative to MVF (RFD/MVF), corrected RF GSL (RFD/GSL),
153 and RF muscle thickness (MT) (RFD/MT) (19, 20, 27). Specific force was calculated as MVF

154 divided by RF MT and absolute MVF was normalized to body mass (BM) to power two-thirds
155 (N/kg^{0.67}) (12).

156

157 *[insert Fig. 1]*

158

159 **Statistical analyses.**

160 Data are presented as mean values \pm SD unless otherwise noted. Normality of each variable
161 was assessed with the Shapiro-Wilk test. Pearson product-moment correlation coefficients (r)
162 were used to determine associations among estimates of knee extensor strength, muscle
163 quality, and physical function. The magnitudes of the correlation coefficients were described as
164 0.00-0.30, 0.30-0.50, 0.50-0.70, 0.70-0.90, and 0.90-1.00 and interpreted as negligible, low,
165 moderate, high, and very high, respectively (23). Statistical significance was set at $p < 0.05$ for
166 two-tailed tests. Statistical analyses were performed using SPSS version 26 (SPSS Inc.,
167 Chicago, IL).

168

169 **RESULTS**

170 Participant characteristics are presented in **Table 1**. Study participants were classified as
171 exhibiting moderately to severely decreased kidney function based on mean eGFR, with 14% of
172 participants classified with CKD stage 3a (n=2), 57% with CKD stage 3b (n=8), and 29% with
173 CKD stage 4 (n=4). According to BMI, 36% of participants were classified as overweight (n=5)
174 while 64% were classified as obese (n=9). Two of the fourteen participants, both classified as
175 CKD stage 4, were unable to complete a single STS repetition and therefore were not included
176 in the STS analysis. eGFR was directly related to the SPPB ($r=0.54$, $p=0.044$) and inversely
177 related to STS ($r=-0.62$, $p=0.029$). No other significant relationships were observed between
178 eGFR and RFD outcomes, MVF, RF GSL, or RF MT (data not shown). RFD data were
179 unavailable on three participants; and therefore, eleven participants were included in the

180 analysis of the relationships between physical function and muscle-specific outcomes with RFD
181 unless otherwise noted. Of the three participants without RFD data, one was not able to
182 complete the STS task.

183

184 *[insert Table 1]*

185

186 *Short Physical Performance Battery (SPPB)*

187

188 Participant RFD estimations are displayed in **Table 2**. **Figure 2** shows the relationships
189 between the SPPB and RFD. SPPB was positively associated with RFD at time points 0-50 ms,
190 50-100 ms, and 0-300 ms (RFD₀₋₅₀, $r=0.73$, $p=0.010$; RFD₅₀₋₁₀₀, $r=0.67$, $p=0.022$ and RFD₀₋₃₀₀
191 $r=0.61$, $p=0.045$); and with RFD/GSL at time points 0-50 ms, 50-100 ms, and 0-300 ms
192 (RFD/GSL₀₋₅₀, $r=0.70$, $p=0.015$; RFD/GSL₅₀₋₁₀₀, $r=0.76$, $p=0.006$ and RFD/GSL₀₋₃₀₀ $r=0.63$,
193 $p=0.035$), respectively. The SPPB was not significantly related to MVF, RF GLS, corrected RF
194 GSL, RF MT, or specific force (data not shown).

195

196 *[insert Table 2]*

197

198 *[insert Fig. 2]*

199

200

201 *Sit-to-Stand (STS)*

202

203 Ten participants are included in the analysis of the relationship between STS and RFD due to
204 two participants being unable to perform the STS assessment and the absence of RFD on three
205 participants (**Figure 3**). The STS was inversely associated with RFD at time points 0-50 ms, 50-

Rate of Force Development and Function in CKD

206 100 ms, and 0-300 ms (RFD₀₋₅₀, $r=-0.78$, $p=0.007$; RFD₅₀₋₁₀₀, $r=-0.78$, $p=0.006$ and RFD₀₋₃₀₀
207 $r=-0.76$, $p=0.009$) and with RFD/MVF at time points 0-50 ms, 50-100 ms, and 0-300 ms
208 (RFD/MVF₀₋₅₀, $r=-0.67$, $p=0.033$; RFD/MVF₅₀₋₁₀₀, $r=-0.80$, $p=0.005$ and RFD/MVF₀₋₃₀₀ $r=-0.73$,
209 $p=0.015$), respectively. The STS was also inversely related to RFD/GSL at time points 0-50 ms,
210 50-100 ms, and 0-300 ms (RFD/GSL₀₋₅₀, $r=-0.71$, $p=0.021$; RFD/GSL₅₀₋₁₀₀, $r=-0.78$, $p=0.008$ and
211 RFD/GSL₀₋₃₀₀ $r=-0.64$, $p=0.042$; respectively) and RFD/MT at time point 0-50 ms (RFD/MT₀₋₅₀,
212 $r=-0.66$, $p=0.034$), respectively. The STS was not significantly related to MVF, RF GSL,
213 corrected RF GSL, RF MT, or specific force (data not shown).

214

215 *[insert Fig. 3]*

216

217 *Maximal Voluntary Force (MVF)*

218

219 **Figure 4** shows the relationships between the MVF and RFD. MVF was positively related to
220 RFD at time points 50-100 ms, 100-200 ms, and 0-300 ms (RFD₅₀₋₁₀₀, $r=0.72$, $p=0.011$; RFD₁₀₀₋
221 ₂₀₀, $r=0.66$, $p=0.025$; and RFD₀₋₃₀₀ $r=0.70$, $p=0.016$); and to RFD/GSL at time points 50-100 ms
222 and 100-200 ms (RFD/GSL₅₀₋₁₀₀, $r=0.71$, $p=0.014$ and RFD/GSL₁₀₀₋₂₀₀, $r=0.62$, $p=0.039$)
223 respectively; but not to RFD/MT (data not shown). Normalized MVF was positively related to
224 RFD/GSL at time points 50-100 ms, 100-200 ms, and 0-300 (RFD/GSL₅₀₋₁₀₀, $r=0.61$, $p=0.042$;
225 RFD/GSL₁₀₀₋₂₀₀, $r=0.62$, $p=0.039$; and to RFD/GSL₀₋₃₀₀, $r=0.64$, $p=0.034$; respectively).

226

227 *[insert Fig. 4]*

228

229 *Muscle Quality*

230

231 Corrected RF GSL was inversely associated with RFD/MVF at time point 0-300 (RFD/MVF₀₋₃₀₀,
232 $r=-0.60$; $p=0.049$) (*data not shown*).

233

234 *Specific Force*

235

236 Specific force was positively associated with RFD at time point 100-200 ms (RFD₁₀₀₋₂₀₀, $r=0.67$,
237 $p=0.022$); and with RFD/GSL at time point 100-200 ms (RFD/GSL₁₀₀₋₂₀₀, $r=0.60$, $p=0.050$) (*data*
238 *not shown*).

239

240 **DISCUSSION**

241

242 Reduced kidney function, as assessed by eGFR, was associated with declines in physical
243 functional assessments. Moderate to strong relationships were found between RFD and SPPB,
244 STS, and MVF. When controlling for MVF, RFD was moderately to strongly associated with STS
245 and moderately related to muscle quality. While RFD was associated with MVF, no significant
246 relationships were observed between measures of MVF and functional outcomes. The findings
247 of the present study suggest that functional performance is significantly related to RFD in middle
248 aged and older men with CKD stages 3 and 4 predialysis.

249

250 The decline in physical function is accelerated in patients with CKD predialysis and ESRD and
251 progressively worsens as kidney function declines (16, 21). Variations of the STS task have
252 been found to be related to aerobic capacity and muscle cross-sectional area in patients with
253 CKD predialysis and ESRD (21, 25). The current results are in agreement with previous findings
254 on STS and CKD in demonstrating an inverse moderately significant relationship between
255 eGFR and STS. The present data extend previous findings, showing inverse, moderately-to-
256 highly significant associations between RFD at time points 0-50 ms, 50-100 ms, and 0-300 ms,

257 and the STS. Moreover, the relationship between RFD and STS was maintained when
258 controlling for maximal force (i.e., MVF) and muscle quality (i.e., RF GSL).

259
260 Limited data are currently available regarding the impact of CKD and ESRD on RFD. Molsted et
261 al. reported that, in dialysis patients, 16-weeks of resistance exercise training increased
262 electromyographic (EMG) amplitude during the 200-300 ms time period following the onset of
263 muscle contraction, with a concomitant increase of 21-38% in RFD of the knee extensors (22).
264 These findings support resistance exercise as a possible treatment option for enhancing RFD in
265 patients with ESRD. Gollie et al. recently highlighted the relative lack of information on the
266 effects of resistance exercise for improving neuromuscular power, as compared to strength and
267 muscle hypertrophy, in patients with CKD predialysis (5). Therefore, additional research is
268 necessary to determine which resistance exercise approaches are most effective for improving
269 RFD and physical function in such patients, and the feasibility and tolerability of such
270 approaches.

271
272 Although peak knee extensor force (i.e., MVF) was not significantly related to functional ability in
273 the current study, it was positively associated with absolute RFD at time points 50-100 ms, 100-
274 200 ms, and 0-300 ms, suggesting that peak isometric knee extensor force has important
275 implications for RFD in adults with CKD predialysis. It has been suggested that voluntary RFD
276 becomes increasingly more dependent on maximal force generating capacity and less
277 dependent on muscle twitch characteristics with increasing time after the onset of contraction (2,
278 3, 20, 27). At time intervals later than 90 ms from the onset of contraction, maximal strength
279 accounted for 52-81% of the variance in RFD. In contrast, in very early time intervals (< 40 ms),
280 RFD was only moderately associated with twitch contractile properties, and was less related to
281 maximal force capacity (2).

282

283 Research on neuromuscular properties in patients with kidney disease has primarily focused on
284 muscle size in the ESRD population on dialysis, due to their increased risk for accelerated
285 muscle loss (34). Johansen et al. demonstrated that decreased gait speed was associated with
286 loss in muscle contractile area and maximal isometric knee extensor strength in ambulatory
287 hemodialysis participants (13). Conversely, John et al. reported that change in muscle cross-
288 sectional area over 2-years was poorly correlated with change in STS (14). In non-dialysis
289 patients, Wilkinson et al. found that muscle quality was inversely related to functional outcomes
290 but that RF cross-sectional area was a better predictor of functional performance when
291 compared to muscle quality (35). Our results posit RFD as an additional variable to aid in
292 understanding the effects of of CKD predialysis on physical function and neuromuscular
293 capacity. The lack of consistency across studies highlights the complexity of neuromuscular
294 complications associated with CKD and the need for further research designed to clarify the
295 relationships between neuromuscular properties and physical function in this patient population.

296

297 *Limitations.* The small sample size and lack of women participants precludes generalization of
298 the current findings beyond our study sample. The absence of control study participants, i.e.
299 individuals without moderate to severe declines in kidney function, limits the ability to determine
300 if, or the extent to which, RFD was compromised because of CKD in our patient population. The
301 instructions to participants in the present study to contract as “hard” as possible may have
302 resulted in an underestimation of RFD capabilities. Lastly, the presence of multiple
303 comorbidities is common in patients with CKD predialysis; consequently, it is unclear how the
304 type and number of comorbidities in our study population may have influenced the findings of
305 the current study.

306

307 **Conclusions**

308 In community-dwelling, middle-aged and older men with CKD stages 3 and 4, RFD is
309 significantly associated with MVF, muscle quality and physical function. Further studies are
310 warranted to determine the responsiveness of RFD to exercise interventions targeting physical
311 function in patients with CKD predialysis and ESRD.

312

313 **Acknowledgments**

314 This study was conducted as part of a VA funded Center of Innovation award (VACI# AM-251)
315 between the San Francisco VAMC and the Washington D.C. VAMC, the aim of which was to
316 investigate clinically viable approaches for the assessment of sarcopenia in Veterans with CKD
317 stages 3 and 4 predialysis (ClinicalTrials.gov NCT03160326).

References

1. **Aggarwal HK, Sood S, Jain D, Kaverappa V, Yadav S.** Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. *Ren Fail* 35: 1323–1329, 2013.
2. **Andersen LL, Aagaard P.** Influence of maximal muscle strength and intrinsic muscle contractile properties on contractile rate of force development. *Eur J Appl Physiol* 96: 46–52, 2006.
3. **Folland JP, Buckthorpe MW, Hannah R.** Human capacity for explosive force production: Neural and contractile determinants: Determinants of explosive force production. *Scand J Med Sci Sports* 24: 894–906, 2014.
4. **Gerstner GR, Thompson BJ, Rosenberg JG, Sobolewski EJ, Scharville MJ, Ryan ED.** Neural and Muscular Contributions to the Age-Related Reductions in Rapid Strength. *Med Sci Sports Exerc* 49: 1331–1339, 2017.
5. **Gollie JM, Harris-Love MO, Patel SS, Argani S.** Chronic kidney disease: considerations for monitoring skeletal muscle health and prescribing resistance exercise. *Clin Kidney J* 11: 822–831, 2018.
6. **Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB.** Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. *N Engl J Med* 332: 556–561, 1995.
7. **Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB.** A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission. *J Gerontol* 49: M85–M94, 1994.
8. **Haff GG, Nimphius S.** Training Principles for Power. *Strength Cond J* 34: 2–12, 2012.
9. **Harris-Love MO, Gonzales TI, Wei Q, Ismail C, Zabal J, Woletz P, DiPietro L, Blackman MR.** Association Between Muscle Strength and Modeling Estimates of Muscle Tissue Heterogeneity in Young and Old Adults. *J Ultrasound Med* 38: 1757–1768, 2018.
10. **Inaguma D, Tanaka A, Shinjo H.** Physical function at the time of dialysis initiation is associated with subsequent mortality. *Clin Exp Nephrol* 21: 425–435, 2017.
11. **Ismail C, Zabal J, Hernandez HJ, Woletz P, Manning H, Teixeira C, DiPietro L, Blackman MR, Harris-Love MO.** Diagnostic Ultrasound Estimates of Muscle Mass and Muscle Quality Discriminate Between Women With and Without Sarcopenia. *Front Physiol* 6, 2015.
12. **Jaric S.** Muscle Strength Testing: Use of Normalisation for Body Size. *Sports Med* 32: 615–631, 2002.
13. **Johansen KL, Shubert T, Doyle J, Soher B, Sakkas GK, Kent-Braun JA.** Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. *Kidney Int* 63: 291–297, 2003.

14. **John SG, Sigrist MK, Taal MW, McIntyre CW.** Natural History of Skeletal Muscle Mass Changes in Chronic Kidney Disease Stage 4 and 5 Patients: An Observational Study. *PLoS ONE* 8: e65372, 2013.
15. **Krishnan AV, Kiernan MC.** Neurological complications of chronic kidney disease. *Nat Rev Neurol* 5: 542–551, 2009.
16. **Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE.** Functional Status of Elderly Adults Before and After Initiation of Dialysis. *N Engl J Med* 361: 1539–1547, 2009.
17. **Kutner NG, Zhang R, Huang Y, Painter P.** Gait Speed and Mortality, Hospitalization, and Functional Status Change Among Hemodialysis Patients: A US Renal Data System Special Study. *Am J Kidney Dis Off J Natl Kidney Found* 66: 297–304, 2015.
18. **Leikis MJ.** Exercise Performance Falls over Time in Patients with Chronic Kidney Disease Despite Maintenance of Hemoglobin Concentration. *Clin J Am Soc Nephrol* 1: 488–495, 2006.
19. **Lopez P, Wilhelm EN, Rech A, Minozzo F, Radaelli R, Pinto RS.** Echo intensity independently predicts functionality in sedentary older men: Muscle Echo Intensity in Older Men. *Muscle Nerve* 55: 9–15, 2017.
20. **Maffiuletti NA, Aagaard P, Blazevich AJ, Folland J, Tillin N, Duchateau J.** Rate of force development: physiological and methodological considerations. *Eur J Appl Physiol* 116: 1091–1116, 2016.
21. **McIntyre CW, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF.** Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc* 21: 2210–2216, 2006.
22. **Molsted S, Andersen JL, Eidemak I, Harrison AP.** Increased rate of force development and neuromuscular activity after high-load resistance training in patients undergoing dialysis: Force development and training in dialysis patients. *Nephrology* 18: 770–776, 2013.
23. **Mukaka MM.** Statistics corner: A guide to appropriate use of correlation coefficient in medical research. *Malawi Med J J Med Assoc Malawi* 24: 69–71, 2012.
24. **Osawa Y, Studenski SA, Ferrucci L.** Knee extension rate of torque development and peak torque: associations with lower extremity function: Rate of torque development and lower extremity function. *J Cachexia Sarcopenia Muscle* 9: 530–539, 2018.
25. **Padilla J, Krasnoff J, Da Silva M, Hsu C-Y, Frassetto L, Johansen KL, Painter P.** Physical functioning in patients with chronic kidney disease. *J Nephrol* 21: 550–559, 2008.
26. **Plantinga LC, Johansen K, Crews DC, Shahinian VB, Robinson BM, Saran R, Burrows NR, Williams DE, Powe NR.** Association of CKD With Disability in the United States. *Am J Kidney Dis* 57: 212–227, 2011.

27. **Rodríguez-Rosell D, Pareja-Blanco F, Aagaard P, González-Badillo JJ.** Physiological and methodological aspects of rate of force development assessment in human skeletal muscle. *Clin Physiol Funct Imaging* 38: 743–762, 2018.
28. **Roshanravan B, Patel KV.** Assessment of physical functioning in the clinical care of the patient with advanced kidney disease. *Semin Dial* 32: 351–360, 2019.
29. **Roshanravan B, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer IH, Ikizler TA, Himmelfarb J, Katzel LI, Kestenbaum B, Seliger S.** Association between Physical Performance and All-Cause Mortality in CKD. *J Am Soc Nephrol* 24: 822–830, 2013.
30. **Sietsema KE, Amato A, Adler SG, Brass EP.** Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease. *Kidney Int* 65: 719–724, 2004.
31. **Stock MS, Whitson M, Burton AM, Dawson NT, Sobolewski EJ, Thompson BJ.** Echo Intensity Versus Muscle Function Correlations in Older Adults are Influenced by Subcutaneous Fat Thickness. *Ultrasound Med Biol* 44: 1597–1605, 2018.
32. **Takai Y, Ohta M, Akagi R, Kanehisa H, Kawakami Y, Fukunaga T.** Sit-to-stand Test to Evaluate Knee Extensor Muscle Size and Strength in the Elderly: A Novel Approach. *J Physiol Anthropol* 28: 123–128, 2009.
33. **van Loon I, Hamaker ME, Boereboom FTJ, Grooteman MPC, Blankestijn PJ, van den Dorpel RMA, Nubé MJ, Ter Wee PM, Verhaar MC, Bots ML.** A closer look at the trajectory of physical functioning in chronic hemodialysis. *Age Ageing* 46: 594–599, 2017.
34. **Wang XH, Mitch WE.** Mechanisms of Muscle Wasting in Chronic Kidney Disease. *Nat Rev Nephrol* 10: 504–516, 2014.
35. **Wilkinson TJ, Gould DW, Nixon DGD, Watson EL, Smith AC.** Quality over quantity? Association of skeletal muscle myosteatosis and myofibrosis on physical function in chronic kidney disease. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.* (June 22, 2018). doi: 10.1093/ndt/gfy139.

Table 1. Participant characteristics (n=14).

Outcome	mean (SD)
Age (years)	71.2 (6.2)
Height (cm)	175.1 (7.3)
Weight (kg)	103.1 (22.1)
BMI (kg/m²)	33.5 (5.9)
eGFR (mL/min per 1.73 m²)	37.5 (10.4)
Potassium (mmol/L)	4.7 (0.6)
SPPB	8.6 (2.4)
STS (s)*	14.8 (3.3)
MVF (N)	371 (78.8)
Normalized MVF (N/kg^{0.67})	16.9 (3.7)
Specific force (N/cm)	16.2 (5.1)
RF GSL (a.u.)	80.4 (10.8)
Corrected RF GSL (a.u.)	132.7 (19.7)
RF MT (cm)	23.9 (5.0)
Subcutaneous fat tissue (cm)	1.3 (0.5)

*n=12 for sit-to-stand (STS) task.

Abbreviations. *eGFR*, estimated glomerular filtration rate; *cm*, centimeters; *kg*, kilogram; *m*, meter; *mg*, milligram; *dl*, deciliter; *g*, gram; *%*, percent; *SPPB*, Short Physical Performance Battery; *STS*, sit-to-stand; *s*, seconds; *MVF*, maximal voluntary force; *N*, Newton; *RF GSL*, rectus femoris grayscale; *a.u.*, arbitrary units; *RF MT*, rectus femoris muscle thickness

Rate of Force Development and Function in CKD

Table 2. Absolute and relative rate of force development (RFD) estimations in male Veterans with CKD stages 3 and 4 (n=11).

Outcome	0-50ms	50-100 ms	100-200 ms	200-300 ms	0-300 ms
RFD (N·s)	1334.7 (713.9)	988.2 (334.9)	727.9 (371.9)	382.5 (226.5)	874.8 (272.2)
RFD/MVF (N·s·N)	3.5 (1.8)	2.5 (0.6)	1.8 (0.8)	1.0 (0.7)	2.2 (0.5)
RFD/GSL (N·s·a.u.)	10.7 (6.8)	7.7 (2.9)	5.8 (3.4)	2.9 (1.8)	6.9 (2.8)
RFD/MT (N·s·cm)	58.0 (35.9)	43.4 (17.3)	33.5 (21.8)	17.3 (12.6)	39.1 (16.5)

Data presented as mean values (SD).

Abbreviations. *RFD*, rate of force development; *RFD/MVF*, rate of force development normalized to maximal voluntary force; *RFD/GSL*, rate of force development normalized to corrected rectus femoris grayscale; *RFD/MT*, rate of force development normalized to rectus femoris muscle thickness; *N*, Newton; *s*, second; *a.u.*, arbitrary unit; *cm*, centimeter.

Figure Legend

Figure 1. Example of a force-time curve during maximal voluntary isometric contraction of the dominant knee extensor depicting the specific time intervals used for assessment. *N*, newton; *ms*, millisecond


Figure 2. Relationship between SPPB and RFD at time intervals 0-50ms (a), 50-100 ms (b), and 0-300 ms (c); and the relationship between SPPB and RFD normalized to corrected RF GSL at time intervals 0-50 ms (d), 50-100 ms (e), and 0-300 ms (f). *RFD*, rate of force development; *GSL*, corrected rectus femoris grayscale; *SPPB*, Short Physical Performance Battery; *N*, Newton; *s*, second; *a.u.*, arbitrary unit.

Figure 3. Relationship between STS and RFD at time intervals 0-50 ms (a), 50-100 ms (b), and 0-300 ms (c); the relationship between STS and RFD/MVF at time intervals 0-50 ms (d), 50-100 ms (e), and 0-300 ms (f); and the relationship between STS and RFD/GSL at time intervals 0-50 ms (g), 50-100 ms (h), and 0-300 ms (i). *RFD*, rate of force development; *MVF*, maximal voluntary force; *GSL*, corrected rectus femoris grayscale; *STS*, Sit-to-Stand; *N*, Newton; *s*, second; *a.u.*, arbitrary unit.

Figure 4. Relationship between RFD and MVF at time intervals 50-100 ms (a), 100-200 ms (b), and 0-300 ms (c); the relationship between RFD/GSL and MVF at time intervals 50-100 ms (d) and 100-200 ms; and the relationship between RFD/GSL and Normalized MVF at time intervals 50-100 ms (f), 100-200 ms (g), and 0-300 ms (h). *RFD*, rate of force development; *GSL*, corrected rectus femoris grayscale; *MVF*, maximal voluntary force. *N*, Newton; *kg*, kilogram; *s*, second; *a.u.*, arbitrary unit.


Rate of Force Development and Function in CKD

Figure 1




Rate of Force Development and Function in CKD

Figure 2



Rate of Force Development and Function in CKD

Figure 3



Rate of Force Development and Function in CKD

Figure 4

